Latest ebit for GKB.BO: $66M, below the sector sector average of $2.4T.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
As of the most recent data (June 2026), GKB.BO shows a EBIT of $66M. That compares with $-49M in the prior-year period — up 235.8% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, GKB.BO's EBIT is now $66M (was $-49M) — a 235.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether GKB Ophthalmics Limited is outperforming or lagging.
The its sector sector average EBIT is about $2.4T. GKB Ophthalmics Limited is at $66M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how GKB.BO stacks up against individual peers as well.
Tracking GKB.BO's ebit over time shows whether GKB Ophthalmics Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $66M That compares with $-49M in the prior-year period — up 235.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has GKB Ophthalmics Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $66M) with ownership activity and broader fundamentals.